Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

Abstract Background Tyrosine kinase inhibitors (TKIs) are effective for the treatment of non‐small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR), but responses are not durable as tumors develop resistance. DS‐1205c is a novel, specific, or...

Full description

Bibliographic Details
Main Authors: Koichi Goto, Yoshimasa Shiraishi, Haruyasu Murakami, Hidehito Horinouchi, Ryo Toyozawa, Masayuki Takeda, Makiko Uno, Nigel Crawford, Joseph McGill, Takeshi Jimbo, Masato Ishigami, Gensuke Takayama, Shintaro Nakayama, Shoichi Ohwada, Makoto Nishio
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Cancer Medicine
Subjects:
AXL inhibitor
DS‐1205
gefitinib
non‐small cell lung cancer
phase I clinical trial
Online Access:https://doi.org/10.1002/cam4.5508

Internet

https://doi.org/10.1002/cam4.5508

Similar Items